ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

Flat NIH Budget Threatens Future Of Research, Universities Say.

March 14, 2008

USC $2.5 Million contract Tops Last Minute FY 75 Rush of Awards

July 18, 1975

Overdiagnosis Since Advent Of Prostate Cancer Screening

September 25, 2009

In Brief: Two Major Appointments Made At Fox Chase; HHS Names Task Force to Look At DRG Research Impact

April 20, 1984

ACS Report Says Drop in Cancer Mortality Saved 898,000 Lives Over 17 Years

June 17, 2011

Bush Vetoes HHS Budget Bill, House Votes To Sustain.

November 23, 2007